Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Agammaglobulinemia 1

Interventions

pembrolizumab 164Carboplatin 136Cisplatin 84Paclitaxel 80Gemcitabine 77Pemetrexed 74Bevacizumab 65Docetaxel 54Fluorouracil 50Oxaliplatin 48Dexamethasone 45durvalumab 42atezolizumab 40Leucovorin 40130-nm albumin-bound paclitaxel 40Capecitabine 38Nivolumab 35Cetuximab 35Rituximab 33Cyclophosphamide 33Injections 31Fulvestrant 30venetoclax 28Prednisone 28Lenalidomide 27enzalutamide 26Irinotecan 25pomalidomide 24Letrozole 24daratumumab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Panzyga × 30 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡